3,3'-di-keto-β-carotene | 14656-56-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3,3'-di-keto-β-carotene
• 英文别名: 4,4'-dihydrorhodoxanthin；3.7.12.16-tetramethyl-1t.18t-bis-(4-oxo-2.2.6-trimethyl-cyclohexen-(6)-yl)-octadecanonaene-(1.3t.5t.7t.9t.11t.13t.15t.17)；3.7.12.16-Tetramethyl-1t.18t-bis-(4-oxo-2.2.6-trimethyl-cyclohexen-(6)-yl)-octadecanonaen-(1.3t.5t.7t.9t.11t.13t.15t.17)；3,3'-dioxo-trans-β-carotene；3,3'-diketocarotene；luteine；3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-4-oxocyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-one
• CAS: 14656-56-5；26543-85-1
• 化学式: C₄₀H₅₂O₂
• 分子量: 564.852
• InChiKey: WMPSHSIMWMNVCV-DKLMTRRASA-N

物化性质

• 沸点：
  708.8±45.0 °C(Predicted)
• 密度：
  1.003±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10.2
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,3'-di-keto-β-carotene 在 二异丁基氢化铝 作用下， 以 正庚烷 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 玉米黄质
  参考文献：
  名称：

  由6-氧代-异佛尔酮合成类胡萝卜素及相关化合物的技术过程。VII。rhodoxanthin和（3个的合成RS，3个RS）从C -zeaxanthin 15环形部件†往最‡

  摘要：

  由6-氧-异佛尔酮合成类胡萝卜素及相关化合物的技术程序。VII。从C 15-环组分1合成视黄质和（3 RS，3 RS）-玉米黄质

  DOI：

  10.1002/hlca.19820650328
• 作为产物：
  描述：

  玫红黄质 在 溶剂黄146 、 锌 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 3,3'-di-keto-β-carotene
  参考文献：
  名称：

  由6-氧代-异佛尔酮合成类胡萝卜素及相关化合物的技术过程。VII。rhodoxanthin和（3个的合成RS，3个RS）从C -zeaxanthin 15环形部件†往最‡

  摘要：

  由6-氧-异佛尔酮合成类胡萝卜素及相关化合物的技术程序。VII。从C 15-环组分1合成视黄质和（3 RS，3 RS）-玉米黄质

  DOI：

  10.1002/hlca.19820650328

文献信息

• Trimethyl-1,4-dioxaspiro[4,5]dec-7-en-8-methanol
  申请人：Hoffmann-La Roche Inc.

  公开号：US03974181A1

  公开（公告）日：1976-08-10

  The compound 7,9,9-trimethyl-1,4-dioxoaspiro [4,5] dec-7-en-8-methanol an intermediate in the preparation of Zeaxanthin and Xanthophyll, known coloring agents for foodstuffs.

  化合物7,9,9-三甲基-1,4-二氧杂螺[4,5]癸-7-烯-8-甲醇是制备玉米黄素和黄质的中间体，这两种物质是食品着色剂。
• Process for Synthesis of (3R,3'R)-Zeaxanthin and (3R,3'S;meso)-Zeaxanthin from (3R,3'R,6'R)-Lutein via (3R)-3',4'-Anhydrolutein
  申请人：Khachik Frederick

  公开号：US20090238933A1

  公开（公告）日：2009-09-24

  (3R, 3′R, 6′R)-Lutein and (3R, 3′R)-zeaxanthin are two dietary carotenoids that are present in most fruits and vegetables commonly consumed in the US and accumulate in the human plasma, major organs, and ocular tissues. Another stereoisomer of (3R, 3′R)-zeaxanthin that is not of dietary origin but is found in the human ocular tissues is (3R, 3′S; meso)-zeaxanthin. There is growing evidence that these carotenoids play an important role in the prevention of age-related macular degeneration (AMD) that is the leading cause of blindness in the U.S. and the Western World. In view of the potential therapeutic application of dietary lutein, (3R, 3′R)-zeaxanthin, and (3R, 3′S; meso)-zeaxanthin, the industrial production of these carotenoids is of considerable importance. The present invention provides a process for the partial synthesis of (3R, 3′R)-zeaxanthin and (3R, 3′S; meso)-zeaxanthin from a readily accessible dehydration product of (3R, 3′R, 6′R)-lutein, namely, (3R)-3′,4′-didehydro-β,β-caroten-3-ol [(3R)-3′,4′-anhydrolutein]. The process involves regioselective hydroboration of (3R)-3′,4′-anhydrolutein to a mixture of (3R, 3′R)-zeaxanthin and (3R, 3′S; meso)-zeaxanthin followed by separation of these carotenoids by enzyme-mediated acylation.

  (3R, 3′R, 6′R)-叶黄素和(3R, 3′R)-玉米黄质是两种膳食类胡萝卜素，存在于美国常见的大多数水果和蔬菜中，并在人类血浆、主要器官和眼组织中积累。另一种立体异构体(3R, 3′S; meso)-玉米黄质虽非膳食来源，但在人眼组织中发现。越来越多的证据表明，这些类胡萝卜素在预防年龄相关性黄斑变性（AMD）方面发挥重要作用，该病是美国和西方世界导致失明的主要原因。鉴于膳食叶黄素、(3R, 3′R)-玉米黄质和(3R, 3′S; meso)-玉米黄质的潜在治疗应用，这些类胡萝卜素的工业生产具有相当重要的意义。本发明提供了一种从(3R, 3′R, 6′R)-叶黄素的易得脱水产物(3R)-3′,4′-去氢β,β-类胡萝卜烯-3-醇[(3R)-3′,4′-anhydrolutein]部分合成(3R, 3′R)-玉米黄质和(3R, 3′S; meso)-玉米黄质的方法。该过程涉及对(3R)-3′,4′-anhydrolutein的区域选择性氢硼化，得到(3R, 3′R)-玉米黄质和(3R, 3′S; meso)-玉米黄质的混合物，然后通过酶介导的酰化分离这些类胡萝卜素。
• Compositions comprising nebivolol
  申请人：MYLAN LABORATORIES, INC

  公开号：EP2174658A1

  公开（公告）日：2010-04-14

  Described is the use of a safe and therapeutically effective amount of a combination of: (i) nebivolol or a pharmaceutically acceptable salt thereof; (ii) at least one hydralazine compound or a pharmaceutically acceptable salt thereof; and (iii) at least one of isosorbide dinitrate and/or isosorbide mononitrate; in the preparation if a medicament for improving NO release in a black patient, which results in reducing mortality associated with cardiovascular disease and improving exercise tolerance or the quality of life.

  描述了安全且治疗有效量的以下物质组合的用途：(i)奈必洛尔或其药学上可接受的盐；(ii)至少一种水拉嗪化合物或其药学上可接受的盐；和(iii)二硝酸异山梨酯和/或单硝酸异山梨酯中的至少一种；用于制备改善黑人患者 NO 释放的药物，从而降低与心血管疾病相关的死亡率，改善运动耐受性或生活质量。
• New Methods for the Synthesis of Oxygenated Carotenoids
  作者：J. D. Surmatis、A. Walser、J. Gibas、U. Schwieter、R. Thommen

  DOI：10.1002/hlca.19700530513

  日期：——

  AbstractSix keto carotenoids (4, 5, 6, 11, 12, and 22) were synthesized from intermediates which were prepared from the condensation products of mesityl oxide and acetoacetic ester. Compounds 4 and 22 can serve as precursors for zeaxanthin, while 5 can be used as an intermediate for xanthophyll. Echinenone and canthaxanthin were prepared by a new approach from vitamin A. Two new types of keto carotenoids with the keto functions incorporated into the unsaturated chain were prepared.
• Hertzberg; Liaaen Jensen, Acta Chemica Scandinavica (1947), 1967, vol. 21, # 1, p. 15 - 41
  作者：Hertzberg、Liaaen Jensen

  DOI：——

  日期：——